The estimated Net Worth of Mark T Iwicki is at least $4.41 Milion dollars as of 26 June 2024. Mr. Iwicki owns over 15,168 units of Kala Bio stock worth over $1,587,805 and over the last 9 years he sold KALA stock worth over $265,693. In addition, he makes $2,556,170 as Chairman of the Board, President a Chief Executive Officer at Kala Bio.
Sign up
Mr. Iwicki KALA stock SEC Form 4 insiders trading
Mark has made over 12 trades of the Kala Bio stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 15,168 units of KALA stock worth $72,048 on 26 June 2024.
The largest trade he's ever made was exercising 73,576 units of Kala Bio stock on 14 April 2023 worth over $534,898. On average, Mark trades about 3,904 units every 69 days since 2015. As of 26 June 2024 he still owns at least 263,755 units of Kala Bio stock.
You can see the complete history of Mr. Iwicki stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Iwicki biography
Mark T. Iwicki serves as Chairman of the Board, President, Chief Executive Officer of the Company. Previously he served as Executive Chairman of our board of directors from April 2015 to September 2015. Prior to joining us, Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.), or Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor/Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation, a biopharmaceutical company. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on our board of directors, Mr. Iwicki also currently serves on the boards of Aimmune Therapeutics, Inc., Merus N.V., Pulmatrix Inc. and Akero Therapeutics, Inc., all publicly-traded companies, and Nimbus Therapeutics, Inc. and Oxeia Biopharmaceuticals, Inc., which are privately-held biotech companies. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.
What is the salary of Mark Iwicki?
As the Chairman of the Board, President a Chief Executive Officer of Kala Bio, the total compensation of Mark Iwicki at Kala Bio is $2,556,170. There are no executives at Kala Bio getting paid more.
How old is Mark Iwicki?
Mark Iwicki is 53, he's been the Chairman of the Board, President a Chief Executive Officer of Kala Bio since 2017. There are 7 older and 11 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
What's Mark Iwicki's mailing address?
Mark's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.
Insiders trading at Kala Bio
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... a Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
What does Kala Bio do?
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
What does Kala Bio's logo look like?
Complete history of Mr. Iwicki stock trades at Aimmune Therapeutics Inc, Merus N.V, Pulmatrix Inc, Kala Bio a Akero Therapeutics Inc
Kala Bio executives and stock owners
Kala Bio executives and other stock owners filed with the SEC include:
-
Mark Iwicki,
Chairman of the Board, President, Chief Executive Officer -
Todd Bazemore,
Chief Operating Officer -
Eric Trachtenberg,
Chief Compliance Officer, General Counsel, Secretary -
Kim Brazzell,
Chief Medical Officer -
Mark T. Iwicki,
Chairman & CEO -
Dr. Kim Brazzell Ph.D.,
Head of R&D and Chief Medical Officer -
Hongming Chen,
Chief Scientific Officer -
Todd Bazemore,
Pres & COO -
Andrew Koven,
Lead Independent Director -
Rajeev Shah,
Independent Director -
Gregory Perry,
Independent Director -
Robert Paull,
Independent Director -
Howard Rosen,
Independent Director -
Gregory Grunberg,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
Mary Reumuth,
Chief Financial Officer, Treasurer -
James Patnoe,
Sr. VP of Market Access, Commercial Operations & Pricing -
Vincent Kosewski,
Sr. VP of Manufacturing & Supply Chain Management -
Michele LaRussa,
Sr. VP of Regulatory Affairs & Quality Assurance -
Kathleen McCann Kline,
Sr. VP of Marketing -
Eric L. Trachtenberg,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jill S. Steier,
Exec. Director of Investor Relations & Corp. Communications -
Mary Reumuth CPA, CPA,
CFO & Treasurer -
Dr. Justin Hanes Ph.D.,
Founder & Chair of the Scientific Advisory Board -
Capital Partners Ii, Llcenr...,
-
Harbor Master Investors (Ca...,
10% owner -
Associates, L.L.C.Caxton Co...,
-
Paulina Hill,
Director -
Advisors Llc Orbi Med Capit...,
-
Capital Management, L.P.Ra ...,
-
Robert I Tepper,
Director -
Robert Langer,
Director -
Advisors Llc Orbi Med Capit...,
-
Michele La Russa,
Sr. VP, Regulatory and Quality -
C. Daniel Myers,
-
Marjan Farid,
-
Capital Management, L.P.Ra ...,
-
Romulus K Brazzell,
SEE REMARKS -
Mark S. Blumenkranz,
-
Darius Kharabi,
CHIEF BUSINESS OFFICER